C.D. Mullins

The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

Background and ObjectiveAdvanced prostate cancer patients with bone metastasis are predisposed to skeletal complications termed skeletal-related events (SREs). There is limited information available on Medicare costs associated with treating SREs. The objective of this study was to ascertain SRE-related costs among older men with metastatic prostate cancer in the US.MethodsWe analysed patients aged 66xa0years or older who were diagnosed with incident stage IV (M1) prostate cancer between 2000 and 2007 from the linked Surveillance, Epidemiology and End Results (SEER)–Medicare dataset. A propensity score for the incidence of an SRE was estimated using a logistic regression model including demographic and clinical baseline variables. Patients with SREs (cases) were matched to patients without SREs (controls) based on the propensity score, length of follow-up (i.e. date of prostate cancer diagnosis to last date of observation) and death. Health resource utilization cost differences between cases and controls over time were compared using generalized linear models. Healthcare costs were examined by type of SRE (pathological fracture only, pathological fracture with concurrent surgery, spinal cord compression only, spinal cord compression with concurrent surgery, and bone surgery only) and by source of care (inpatient, physician/non-institutional provider, skilled nursing facility, outpatient and hospice). All costs were adjusted to 2009 US dollars, using the medical care component of the Consumer Price Index.ResultsApplication of the inclusion criteria resulted in 1,131 metastatic prostate cancer patients with SREs and 6,067 patients without SREs during follow-up. The average age of the sample was 79xa0years, and 14xa0% were African American. A total of 928 patients with SREs were matched to 928 patients without SREs. The average health care utilization cost of patients with SREs was US

Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

29,696 (95xa0% confidence interval [CI] US

PCV134 READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING

24,730–US

PCN12 TIMING OF PHYSICIAN VISITS AND THE IMPACT ON SURVIVAL AMONG SEER-MEDICARE PATIENTS WITH STAGE IV PROSTATE CANCER

34,662) higher than that of the controls. The most expensive SRE group was spinal cord compression with concurrent surgery (US

PMC36 THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND SEER-MEDICARE DATA

82,868: 95xa0% CI US

PCV31: ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS

67,472–US

EV1 DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)

98,264) followed by bone surgery only (US

Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer

37,496: 95xa0% CI US

The Use Of Transarterial Chemoembolization For Treating Hepatocellular Carcinoma In The Seer-Medicare Population

29,684–US

PCN106 Development of a Guidance for Including Patient-Reported Outcomes (PROs) in Late-Phase Adult Clinical Trials of Oncology Drugs for Comparative Effectiveness Research (CER)

45,308), pathological fracture with concurrent surgery (US